The 2024 guidelines of the European Society of Cardiology (ESC) refer to four very important therapeutic areas: arterial hypertension, atrial fibrillation, chronic coronary syndromes and peripheral artery disease. The ESC countries and their institutional members share a common goal of reducing the burden of cardiovascular diseases, which remain the leading cause of death worldwide. Experts from these six countries - three from Europe and three from Asia - gathered at the annual meeting to briefly present the epidemiological situation regarding selected issues addressed in the 2024 ESC guidelines, and to create a document highlighting the significant progress in pharmacotherapy. The new guidelines allow us to identify particularly important therapeutic areas and unmet pharmaceutical needs within the four treatment guidelines developed by the ESC in 2024. While discussing each of these four documents, 10 subjectively selected points were chosen to highlight what should be kept in mind in daily clinical practice. Altogether, a range of all-risk categories are represented, and the observations made in this position paper are of a universal nature.